Related Experiment Video

Updated: Apr 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Nationwide reduction in the frequency of severe hypoglycemia by half

S Fredheim1, A Johansen, S U Thorsen

  • 1Department of Pediatrics, Herlev Hospital, Arkaden, Turkisvej 14, 2730, Herlev, Copenhagen, Denmark, sirifredheim@dadlnet.dk.

Acta Diabetologica
|December 22, 2014
PubMed

Insights

Severe hypoglycemia rates in children with type 1 diabetes halved nationwide between 2008-2013. Insulin pump use significantly reduced severe hypoglycemia events compared to pen treatments.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Mellitus Research
  • Public Health Epidemiology

Background:

  • Severe hypoglycemia (SH) is a significant concern in pediatric type 1 diabetes (T1D) management.
  • Understanding contemporary SH rates and predictors is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate current severe hypoglycemia incidence in Danish children with T1D.
  • To identify factors influencing severe hypoglycemia rates in this population.

Main Methods:

  • A nationwide register-based study utilizing data from the Danish National Diabetes Register (2008-2013).
  • Analysis of 7,390 person-years of data from 2,715 children with T1D.
  • Robust Poisson regression models were employed to assess incidence rates and predictors.

Main Results:

  • The overall incidence of SH was 7.6 per 100 person-years, with a notable decrease from 16.0 in 2008 to 4.9 in 2011.
  • Insulin pump therapy was associated with a 27% reduction in SH rates compared to pen-based insulin delivery (P=0.003).
  • Premixed and NPH insulin use increased SH risk, while long-acting insulin analogues showed no significant difference versus pump use. No association was found between SH and glycemic control (HbA1c).

Conclusions:

  • A significant nationwide reduction in severe hypoglycemia rates was observed in pediatric T1D patients during the study period.
  • These improvements occurred independently of average glycemic control levels.
  • Evolving diabetes care practices and educational initiatives are likely contributors to the decreased SH incidence.
Abstract

More Related Videos

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
3
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
2
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K